Daniel E. Bergsagel

3.4k total citations
73 papers, 2.6k citations indexed

About

Daniel E. Bergsagel is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Daniel E. Bergsagel has authored 73 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Hematology, 27 papers in Oncology and 25 papers in Molecular Biology. Recurrent topics in Daniel E. Bergsagel's work include Multiple Myeloma Research and Treatments (32 papers), Peptidase Inhibition and Analysis (14 papers) and Protein Degradation and Inhibitors (10 papers). Daniel E. Bergsagel is often cited by papers focused on Multiple Myeloma Research and Treatments (32 papers), Peptidase Inhibition and Analysis (14 papers) and Protein Degradation and Inhibitors (10 papers). Daniel E. Bergsagel collaborates with scholars based in Canada, United States and United Kingdom. Daniel E. Bergsagel's co-authors include E. A. McCulloch, R. Hasselback, R. Neil MacDonald, Anthony B. Miller, G. R. Langley, A Bailey, Andrew R. Belch, Makio Ogawa, Philip J. Migliore and Fred Valeriote and has published in prestigious journals such as Science, New England Journal of Medicine and Journal of Clinical Oncology.

In The Last Decade

Daniel E. Bergsagel

71 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel E. Bergsagel Canada 28 1.6k 1.2k 1.1k 382 205 73 2.6k
Raymond Powles United Kingdom 10 2.2k 1.4× 1.1k 0.9× 1.4k 1.3× 332 0.9× 152 0.7× 14 2.5k
Joseph Michaeli United States 18 722 0.5× 694 0.6× 912 0.8× 248 0.6× 116 0.6× 55 2.0k
James S. Hewlett United States 23 812 0.5× 668 0.5× 534 0.5× 284 0.7× 282 1.4× 53 1.8k
Michael Loughnan Australia 11 937 0.6× 602 0.5× 1.2k 1.1× 279 0.7× 174 0.8× 24 2.7k
Arthur Haut United States 24 913 0.6× 1.0k 0.8× 601 0.5× 549 1.4× 804 3.9× 48 2.3k
Kazuyuki Shimizu Japan 17 2.6k 1.7× 1.8k 1.4× 1.7k 1.6× 456 1.2× 357 1.7× 67 3.5k
Peter Gimsing Denmark 31 2.1k 1.3× 1.4k 1.2× 1.9k 1.7× 301 0.8× 176 0.9× 111 3.1k
Donna Weber United States 23 1.8k 1.1× 1.2k 1.0× 1.5k 1.3× 378 1.0× 229 1.1× 79 2.7k
LL Sensenbrenner United States 24 1.2k 0.8× 500 0.4× 376 0.3× 426 1.1× 238 1.2× 67 2.0k
J Treleaven United Kingdom 28 1.1k 0.7× 515 0.4× 397 0.4× 291 0.8× 149 0.7× 71 2.0k

Countries citing papers authored by Daniel E. Bergsagel

Since Specialization
Citations

This map shows the geographic impact of Daniel E. Bergsagel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel E. Bergsagel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel E. Bergsagel more than expected).

Fields of papers citing papers by Daniel E. Bergsagel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel E. Bergsagel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel E. Bergsagel. The network helps show where Daniel E. Bergsagel may publish in the future.

Co-authorship network of co-authors of Daniel E. Bergsagel

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel E. Bergsagel. A scholar is included among the top collaborators of Daniel E. Bergsagel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel E. Bergsagel. Daniel E. Bergsagel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bergsagel, Daniel E.. (2001). Myeloma: what have we learned?. Biomedicine & Pharmacotherapy. 55(9-10). 548–549. 2 indexed citations
2.
Gale, Robert Peter, Rolla Edward Park, Robert W. Dubois, et al.. (1999). Delphi-Panel Analysis of Appropriateness of High-Dose Therapy and Bone Marrow Autotransplants in Newly Diagnosed Multiple Myeloma. Leukemia & lymphoma. 33(5-6). 511–519. 5 indexed citations
3.
Malpas, J. S., Daniel E. Bergsagel, & Robert A. Kyle. (1995). Myeloma : biology and management. Oxford University Press eBooks. 78 indexed citations
4.
Browman, George P., Daniel E. Bergsagel, Séamus O’Reilly, et al.. (1995). Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group.. Journal of Clinical Oncology. 13(9). 2354–2360. 76 indexed citations
5.
Bergsagel, Daniel E.. (1995). 5The role of chemotherapy in the treatment of multiple myeloma. Baillière s Clinical Haematology. 8(4). 783–794. 12 indexed citations
6.
Kiss, Thomas, Jeffrey H. Lipton, Daniel E. Bergsagel, et al.. (1994). Determination of IL6, IL1, and IL4 in the Plasma of Patients with Multiple Myeloma. Leukemia & lymphoma. 14(3-4). 335–340. 16 indexed citations
7.
Sklarin, Nancy T., William R. Grove, Abraham Mittelman, et al.. (1992). A phase II trial of CI-921 in advanced malignancies. Investigational New Drugs. 10(4). 309–312. 19 indexed citations
8.
Belch, Andrew R., Daniel E. Bergsagel, Kenneth S. Wilson, et al.. (1991). Effect of daily etidronate on the osteolysis of multiple myeloma.. Journal of Clinical Oncology. 9(8). 1397–1402. 145 indexed citations
9.
Bergsagel, Daniel E.. (1990). Chronic myelogenous leukemia: an overview. Journal of Cancer Research and Clinical Oncology. 116(1). 104–105. 4 indexed citations
10.
Bergsagel, Daniel E.. (1989). Is aggressive chemotherapy more effective in the treatment of plasma cell myeloma?. European Journal of Cancer and Clinical Oncology. 25(2). 159–161. 42 indexed citations
11.
Bergsagel, Daniel E.. (1988). Interferon alfa-2b in the management of chronic granulocytic leukemia. Cancer Treatment Reviews. 15. 15–20. 3 indexed citations
12.
Bergsagel, Daniel E.. (1988). Chemotherapy of myeloma: Drug combinations versus single agents, an overview, and comments on acute leukemia in myeloma. Hematological Oncology. 6(2). 159–166. 30 indexed citations
13.
Bergsagel, Daniel E.. (1985). Controversies in the treatment of plasma cell myeloma. Postgraduate Medical Journal. 61(712). 109–116. 21 indexed citations
14.
Bergsagel, Daniel E.. (1975). Mouse Myeloma. Archives of Internal Medicine. 135(1). 109–109. 11 indexed citations
15.
Ogawa, Makio, Daniel E. Bergsagel, & E. A. McCulloch. (1973). Sensitivity of Human and Murine Hemopoietic Precursor Cells to Chemotherapeutic Agents Assessed in Cell Culture. Blood. 42(6). 851–856. 22 indexed citations
16.
Bergsagel, Daniel E.. (1972). Plasma cell myeloma. An interpretive review. Cancer. 30(6). 1588–1594. 25 indexed citations
17.
Alexanian, Raymond, Daniel E. Bergsagel, Philip J. Migliore, William K. Vaughn, & Clifton D. Howe. (1968). Melphalan Therapy for Plasma Cell Myeloma. Blood. 31(1). 1–10. 112 indexed citations
18.
Bergsagel, Daniel E., Kenneth M. Griffith, Arthur Haut, & W. J. Stuckey. (1967). The Treatment of Plasma Cell Myeloma. Advances in cancer research. 10. 311–359. 47 indexed citations
19.
Bergsagel, Daniel E., Philip J. Migliore, & Kenneth M. Griffith. (1965). Response : Melphalan and Antigenic Type of Bence Jones Proteins in Myeloma. Science. 149(3683). 565–565. 1 indexed citations
20.
Sutow, Wataru W., M. E. Haggard, Russell J. Blattner, et al.. (1962). Studies of ACTH, hydrocortisone, and 6-mercaptopurine in the treatment of children with acute leukemia. The Journal of Pediatrics. 61(5). 693–701. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Raymond Powles Breakdown of academic impact, for papers by Joseph Michaeli Breakdown of academic impact, for papers by James S. Hewlett Breakdown of academic impact, for papers by Michael Loughnan Breakdown of academic impact, for papers by Arthur Haut Breakdown of academic impact, for papers by Kazuyuki Shimizu Breakdown of academic impact, for papers by Peter Gimsing Breakdown of academic impact, for papers by Donna Weber Breakdown of academic impact, for papers by LL Sensenbrenner Breakdown of academic impact, for papers by J Treleaven
Rankless by CCL
2026